- €4.09bn
- €4.64bn
- $3.95bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.26 | ||
| PEG Ratio (f) | 1.41 | ||
| EPS Growth (f) | 10.34% | ||
| Dividend Yield (f) | 2.6% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.46 | ||
| Price to Tang. Book | 12.02 | ||
| Price to Free Cashflow | 16.68 | ||
| Price to Sales | 1.2 | ||
| EV to EBITDA | 14.26 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.26% | ||
| Return on Equity | 8.99% | ||
| Operating Margin | 5.76% | ||
Financial Summary
| Year End 3rd Jan | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,960.43 | 5,943.7 | 5,425.4 | 3,839.7 | 3,946.4 | 4,037.61 | 4,200.65 | -1.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +27.19 | +22.04 | +10.21 | +16.32 | +0.59 | +10.9 | +8.46 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Glanbia plc is an Ireland-based nutrition company. The Company’s segments include Performance Nutrition, Health and Nutrition, and Dairy Nutrition. The Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products through a variety of channels including specialty, online, Food, Drug, Mass, Club (FDMC), and distributor in a variety of formats, including powders, Ready-to-Eat (bars and snacking foods) and Ready-to-Drink beverages. The Health and Nutrition segment is a global nutritional solutions business, providing value-added ingredients and flavor solutions. The Dairy Nutrition segment is a producer of whey protein isolate and American-style cheddar cheese in the United States and provides a wide range of dairy and functional protein solutions. Its portfolio of brands includes Optimum Nutrition, Isopure, Nutramino, think!, and others.
Directors
- Donard Gaynor NEC (64)
- Mark Garvey FID (56)
- Jim Bergin CEX (58)
- Hugh McGuire CEX (50)
- Brian Phelan CEX (54)
- Siobhan Talbot MDR (57)
- Michael Patten DHR (58)
- Michael Horan SEC (56)
- Patsy Ahern NED (63)
- Roisin Brennan NED (56)
- Vincent Gorman NED (64)
- Brendan Hayes NED (60)
- John Murphy NED (61)
- John Murphy NED (61)
- Patrick Murphy NED (62)
- Patrick Coveney NID (50)
- Jane Lodge NID (65)
- Daniel O'Connor NID (62)
- Last Annual
- January 3rd, 2026
- Last Interim
- January 3rd, 2026
- Incorporated
- March 10th, 1988
- Public Since
- March 1st, 1988
- No. of Employees
- 5,800
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
Irish Stock Exchange- Shares in Issue
- 243,226,476
- Address
- Glanbia House, Ring Road, KILKENNY
- Web
- https://www.glanbia.com/
- Phone
- +353 567772200
- Contact
- Liam Hennigan
- Auditors
- Deloitte Ireland LLP
Latest News for GL9
Upcoming Events for GL9
Glanbia PLC Annual Shareholders Meeting
Glanbia PLC Annual Shareholders Meeting
Half Year 2026 Glanbia PLC Earnings Release
Similar to GL9
Donegal Investment
Irish Stock Exchange
Kerry
Irish Stock Exchange
Origin Enterprises
Irish Stock Exchange
FAQ
As of Today at 19:51 UTC, shares in Glanbia are trading at €16.82. This share price information is delayed by 15 minutes.
Shares in Glanbia last closed at €16.82 and the price had moved by +59.46% over the past 365 days. In terms of relative price strength the Glanbia share price has outperformed the FTSE Global All Cap Index by +40.08% over the past year.
The overall consensus recommendation for Glanbia is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Glanbia dividend yield is 3.99% based on the trailing twelve month period.
Last year, Glanbia paid a total dividend of $0.78, and it currently has a trailing dividend yield of 3.99%.Looking ahead, the next dividend pay date is 2026-04-30.
We do not have data on when Glanbia is to next pay dividends. The historic dividend yield on Glanbia shares is currently 3.99%.
To buy shares in Glanbia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €16.82, shares in Glanbia had a market capitalisation of €4.09bn.
Here are the trading details for Glanbia:
- Country of listing: Ireland
- Exchange: ISE
- Ticker Symbol: GL9
Based on an overall assessment of its quality, value and momentum Glanbia is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Glanbia is €18.72. That is 11.3% above the last closing price of €16.82.
Analysts covering Glanbia currently have a consensus Earnings Per Share (EPS) forecast of $1.44 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glanbia. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +11.71%.
As of the last closing price of €16.82, shares in Glanbia were trading +15.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Glanbia PE ratio based on its reported earnings over the past 12 months is 13.26. The shares last closed at €16.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Glanbia's management team is headed by:
- Donard Gaynor - NEC
- Mark Garvey - FID
- Jim Bergin - CEX
- Hugh McGuire - CEX
- Brian Phelan - CEX
- Siobhan Talbot - MDR
- Michael Patten - DHR
- Michael Horan - SEC
- Patsy Ahern - NED
- Roisin Brennan - NED
- Vincent Gorman - NED
- Brendan Hayes - NED
- John Murphy - NED
- John Murphy - NED
- Patrick Murphy - NED
- Patrick Coveney - NID
- Jane Lodge - NID
- Daniel O'Connor - NID